Stock market today: S&P 500 closes at fresh record ahead of Nvidia earnings
Meredith (NYSE:MDP) Cook, Senior Vice President and General Counsel at ANI Pharmaceuticals (NASDAQ:ANIP), recently sold 400 shares of the company’s common stock. The $1.39 billion market cap pharmaceutical company has seen its stock surge 23% year-to-date, trading near its 52-week high of $70. The transaction, which took place on April 14, 2025, was executed at a price of $68.96 per share, totaling approximately $27,583. Following this sale, Cook retains ownership of 80,145 shares in the company. This sale was conducted under a pre-established Rule 10b5-1 trading plan, which Cook adopted on September 17, 2024. According to InvestingPro data, analysts maintain a bullish outlook on ANIP, with price targets ranging from $62 to $94 per share. Get deeper insights into insider trading patterns and comprehensive analysis with InvestingPro’s detailed research reports.
In other recent news, 3SBio reported a 17% year-over-year increase in revenue for the fiscal year 2024, reaching Rmb9.1 billion, along with a 35% rise in net profit to Rmb2.1 billion. Citi analyst Wanngbin Zhou upgraded 3SBio’s stock rating from Neutral to Buy and raised the price target to HK$13.00, citing strong financial results and promising product developments. Meanwhile, ANI Pharmaceuticals announced the launch of generic Nitazoxanide Tablets, a move that aligns with its strategy to expand its generics market presence. The U.S. annual sales for this product are estimated at approximately $36.1 million. Additionally, ANI Pharmaceuticals settled a $17.25 million royalty obligation with SWK Funding LLC, enhancing its financial flexibility. The FDA also approved an updated label for ANI’s ILUVIEN, expanding its use to include treatment for chronic non-infectious uveitis affecting the posterior segment of the eye. Furthermore, Jefferies initiated coverage on ANI Pharmaceuticals with a Buy rating and an $80 price target, highlighting the company’s growth potential in branded rare disease products. These developments reflect significant strategic and financial activities for both 3SBio and ANI Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.